Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for 'large' cribriform prostatic adenocarcinoma

التفاصيل البيبلوغرافية
العنوان: Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for 'large' cribriform prostatic adenocarcinoma
المؤلفون: Emily Chan, Jesse K. McKenney, Sarah Hawley, Dillon Corrigan, Heidi Auman, Lisa F. Newcomb, Hilary D. Boyer, Peter R. Carroll, Matthew R. Cooperberg, Eric Klein, Ladan Fazli, Martin E. Gleave, Antonio Hurtado-Coll, Jeffry P. Simko, Peter S. Nelson, Ian M. Thompson, Maria S. Tretiakova, Dean Troyer, Lawrence D. True, Funda Vakar-Lopez, Daniel W. Lin, James D. Brooks, Ziding Feng, Jane K. Nguyen
المصدر: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, vol 35, iss 8
بيانات النشر: Elsevier BV, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Prostatectomy, Male, Clinical Research, Pathology, Humans, Prostatic Neoplasms, Adenocarcinoma, Neoplasm Grading, Medical and Health Sciences, Retrospective Studies, Cancer, Pathology and Forensic Medicine
الوصف: Cribriform growth pattern is well-established as an adverse pathologic feature in prostate cancer. The literature suggests "large" cribriform glands associate with aggressive behavior; however, published studies use varying definitions for "large". We aimed to identify an outcome-based quantitative cut-off for "large" vs "small" cribriform glands. We conducted an initial training phase using the tissue microarray based Canary retrospective radical prostatectomy cohort. Of 1287 patients analyzed, cribriform growth was observed in 307 (24%). Using Kaplan-Meier estimates of recurrence-free survival curves (RFS) that were stratified by cribriform gland size, we identified 0.25 mm as the optimal cutoff to identify more aggressive disease. In univariable and multivariable Cox proportional hazard analyses, size >0.25 mm was a significant predictor of worse RFS compared to patients with cribriform glands ≤0.25 mm, independent of pre-operative PSA, grade, stage and margin status (p 0.25 mm had a significantly lower RFS relative to patients with cribriform glands ≤0.25 mm (each subset p = 0.004). Furthermore, there was no significant difference in outcomes between patients with cribriform glands ≤ 0.25 mm and patients without cribriform glands. The >0.25 mm cut-off was validated as statistically significant in a separate 419 patient, completely embedded whole-section radical prostatectomy cohort by biochemical recurrence, metastasis-free survival, and disease specific death, even when cases with admixed Gleason pattern 5 carcinoma were excluded. In summary, our findings support reporting cribriform gland size and identify 0.25 mm as an optimal outcome-based quantitative measure for defining "large" cribriform glands. Moreover, cribriform glands >0.25 mm are associated with potential for metastatic disease independent of Gleason pattern 5 adenocarcinoma.
وصف الملف: application/pdf
تدمد: 0893-3952
DOI: 10.1038/s41379-022-01009-7
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::896631094789ab7a5c5fa3e3c9758783
https://doi.org/10.1038/s41379-022-01009-7
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....896631094789ab7a5c5fa3e3c9758783
قاعدة البيانات: OpenAIRE
الوصف
تدمد:08933952
DOI:10.1038/s41379-022-01009-7